Navigation Links
Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke
Date:5/15/2008

The REACH Registry reveals that 70% of deaths in the stable stroke

population were due to a cardiovascular event other than stroke

NICE, France, May 15 /PRNewswire/ -- New two-year data from the REACH Registry presented at the European Stroke Congress, highlight that among those who die after a stroke the vast majority (73%) will die from nonstroke cardiovascular (CV) events. The overall death rate is 4.45%, with 3.23% of these CV deaths from a nonstroke event.

The two-year data from the REACH Registry demonstrate that the risk of secondary ischemic events (including CV death) is very high in patients with previous stroke and/or TIA.

The REACH Registry has demonstrated that there is a high prevalence of atherothrombosis in more than one vascular bed: one-quarter of patients with coronary artery disease (CAD), two-fifths of patients with cerebrovascular disease (CVD) and three-fifths of patients with peripheral artery disease (PAD) also have atherothrombosis in other arterial locations. REACH Registry data also highlight the undertreatment of patients with CVD in the real-world setting. Improving ischemic risk management in these patients is required to prevent hospitalization and death.

Approximately 28% of patients in the REACH Registry have diagnosed CVD at baseline. About 40% of patients with CVD have polyvascular disease. Of the total CVD population at baseline: 71% suffered a prior stroke; 51% had a prior TIA; and, 20% had both.

Two-year data in the CVD population show high event rates for non-fatal stroke (5.9%). The risk of stroke, MI and CV death at two years was 11.5% for the total CVD population. Patients with a history of CVD are at considerable risk of major adverse cardiac events (MACE) and hospitalizations (>20% at two years).

"CVD patients are at high risk of recurrent stroke and other atherothrombotic events. Moreover the REACH Registry has shown that most of these stable stroke patients are a
'/>"/>

SOURCE REACH Registry
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)
2. Biomatricas RNAstable(TM) Stabilizes RNA at Room Temperature
3. Altogen Biosystems Launches Custom Biotechnology Research Services: Generation of Stable Cell Lines and RNAi Cell Transfection Services
4. D-Pharm Completes Pre-IND Meeting With the FDA for Treatment of Acute Stroke With DP-b99
5. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
10. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
11. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) announced ... Form 20-F for the fiscal year ended December 31, ... The annual report on Form 20-F contains information regarding ... the area of cancer immune checkpoints. This project aims ... specificity and binding in targeting certain identified immune checkpoints. ...
(Date:5/4/2015)... Boston, MA (PRWEB) May 04, 2015 ... solutions for drug discovery and life science research, ... 5.0 , the latest version of its enterprise ... for biopharma R&D enables more efficient discovery and ... holistic approach to integrate and address protein optimization ...
(Date:5/4/2015)...   Tocagen Inc. , a clinical-stage immuno-oncology ... ongoing investigational studies were presented at the 11 th ... of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) ... Washington, D.C. In addition, ... FDA and continues to advance towards initiation of ...
(Date:5/1/2015)... N.C. (PRWEB) May 01, 2015 ... Charlotte (UNC Charlotte) spin-out company, announced that Pinku Mukherjee, ... the UNC Board of Governors’ highest faculty honor. ... to humanity’s welfare , for her innovative research and ... Max Gardner Award represents a crowning moment in my ...
Breaking Biology Technology:Tikcro Technologies Files Annual Report on Form 20-F for the Year Ended December 31, 2014 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5OncoTAb CSO Awarded the University of North Carolina’s O. Max Gardner Award 2
... Imaging,Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS), ... I returned to the company three months ago to,assume ... Board; we have,received many phone calls from our shareholders ... my first priority, I have,recently secured a tiered debenture ...
... Conn., Aug. 5 Marinus Pharmaceuticals, a,developer of ... disorders, has appointed John Krayacich as president,and chief ... leading,the company,s drug and business development for ganaxolone, ... and chelerythrine, a pre-clinical,schizophrenia candidate., Mr. Krayacich ...
... Group, P.A., Deliver Faster Recovery,Fewer Complications for ... Aug. 5 Thoracic Group, P.A., (http://www.thoracicgroup.com ... services,and a national leader of minimally-invasive video ... completion of its 5,000th VATS,surgical procedure. Highly ...
Cached Biology Technology:CEO's Letter to Shareholders of Imaging Diagnostic Systems, Inc. 2CEO's Letter to Shareholders of Imaging Diagnostic Systems, Inc. 3CEO's Letter to Shareholders of Imaging Diagnostic Systems, Inc. 4Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer 2Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer 3Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer 4Renowned NJ-Based Video Assisted Thoracic Surgery (VATS) Team Completes 5,000th Successful Procedure 2Renowned NJ-Based Video Assisted Thoracic Surgery (VATS) Team Completes 5,000th Successful Procedure 3
(Date:4/10/2015)... DUBLIN , April 10, 2015 ... the addition of the "Security Competitive Profiles - ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to ... solutions to the market, with a company focus on ... solution anticipated. Winning opportunities in the ...
(Date:4/8/2015)...  Infinisource, a leading provider of SaaS-based Human Capital ... leading supplier of biometric identification and security solutions, ... advanced biometrically-enabled time clock, the companies announced today. ... setting a bold, new standard for the collection ... and mid-size employer. When connected to the iSolved ...
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... Catching a football. Maneuvering through a room full of ... fore. Most would agree these seemingly simple actions require us ... of Cognitive Science at Rensselaer Polytechnic Institute Mark Changizi argues ... It takes our brain nearly one-tenth of a second to ...
... hold empirical knowledge that tuna aggregate under floating objects, ... or even large marine mammals. There is still no ... 20 years have seen purse-seine fishery operators take advantage ... floating rafts equipped with buoys which act as FADs. ...
... in green tea may be able to stave off ... (OSA), according to a new study published in the ... American Journal of Respiratory and Critical Care Medicine. ... through drinking water, on rats who were intermittently deprived ...
Cached Biology News:Crystal (eye) ball: Study says visual system equipped with 'future seeing powers' 2Crystal (eye) ball: Study says visual system equipped with 'future seeing powers' 3Does fishing on drifting fish aggregation devices endanger the survival of tropical tuna? 2Does fishing on drifting fish aggregation devices endanger the survival of tropical tuna? 3Green tea compounds beat OSA-related brain deficits 2
Rabbit polyclonal to Peptide E ( Abpromise for all tested applications)....
Mouse monoclonal [6911] to E. coli K99 pilus ( Abpromise for all tested applications)....
...
...
Biology Products: